Tamoxifen treatment causes early hepatic insulin resistance
Sign Up to like & getrecommendations! Published in 2020 at "Acta Diabetologica"
DOI: 10.1007/s00592-019-01468-6
Abstract: Tamoxifen is widely used as an effective adjuvant treatment and prevention of estrogen receptor-positive breast cancer [1]. Tamoxifen decreases food intake, body weight and (at least in the short-term) fat mass in rodents. Despite lowering… read more here.
Keywords: treatment; tamoxifen; tamoxifen treatment; early hepatic ... See more keywords